- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.04. | Nxera Pharma: Notice of Issuance of New Shares Under the Restricted Stock Unit (RSU) Plan and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Previous Years' RSU Plan | 1 | GlobeNewswire (USA) | ||
| 16.04. | Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568 | 114 | GlobeNewswire (Europe) | NBI-1117568 is an oral, selective muscarinic M4 receptor agonist advancing through Phase 2 clinical development under a multi-program collaboration with Neurocrine BiosciencesSuccessful completion... ► Artikel lesen | |
| 15.04. | Nxera and Handok partner for PIVLAZ supply in South Korea | 1 | Pharmaceutical Technology | ||
| 15.04. | Nxera Pharma Announces Supply And Distribution Deal With Handok For PIVLAZ In South Korea | 1 | RTTNews | ||
| 15.04. | Nxera Pharma Announces Exclusive Supply and Distribution Agreement with Handok for PIVLAZ in South Korea | 170 | GlobeNewswire (Europe) | PIVLAZ is the first drug approved in South Korea for the prevention of Cerebral Vasospasm in patients with Aneurysmal Subarachnoid Hemorrhage (aSAH)PIVLAZ will become commercially available in South... ► Artikel lesen | |
| 08.04. | Nxera Pharma joins the World Orphan Drug Alliance | 113 | GlobeNewswire (Europe) | Nxera Pharma to represent WODA in Japan and South Korea WODA offers a 'one-stop' solution for biopharma companies seeking to commercialize rare or orphan medicines across global markets Tokyo... ► Artikel lesen | |
| 03.04. | Nxera Pharma Appoints Experienced Senior Strategy Consultant Patrick Branch as Head of Business Development for Japan and APAC | 1 | GlobeNewswire (USA) | ||
| 01.04. | Nxera Pharma is the New Name for Sosei Group | 125 | GlobeNewswire (Europe) | New name expresses the Company's vision to lead the next era of medicine - from Japan, for Japan, and by extension, to the world - and its mission to accelerate the development of life-changing medicines... ► Artikel lesen | |
| 27.03. | Sosei Group Corporation: Sosei Heptares Confirms Re-election of its Board and Executive Management Team and the Approval of Change of Company Name to Nxera Pharma | 91 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 27 March 2024 - Sosei Group Corporation ("the Company"; TSE: 4565) announces that the re-election of its Board of Directors and Executive Officers was approved at the... ► Artikel lesen | |
| 21.03. | Sosei Group Regains Full Ownership From GSK Of Clinic-Ready GPR35 Agonist For Inflammatory Bowel Disease | 479 | AFX News | LONDON (dpa-AFX) - Sosei Group Corp. said it has regained full ownership from GSK of HTL0027477 (formerly GSK4381406), a clinic-ready, highly selective, first-in-class, oral GPR35 agonist in... ► Artikel lesen | |
| 21.03. | Sosei Group Corporation: Sosei Heptares Doses First Subject in Phase 1 Trial with HTL0033744, an EP4 Agonist for Inflammatory Bowel Disease | 83 | GlobeNewswire (Europe) | HTL0033744 has been designed by Sosei Heptares to promote mucosal healing and resolve inflammation in people with IBD Tokyo, Japan and Cambridge, UK, 21 March 2024 - Sosei Group Corporation ("Sosei... ► Artikel lesen | |
| 21.03. | Sosei Group Corporation: Sosei Heptares Regains Full Ownership from GSK of HTL0027477, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease | 89 | GlobeNewswire (Europe) | GPR35 is a novel target with an established genetic association to IBDUK regulatory approval received to commence first-in-human studiesReturn of rights follows change in immunology research strategy... ► Artikel lesen | |
| 11.03. | Boehringer, Sosei Heptares team up in schizophrenia drug deal | 9 | BioPharma Dive | ||
| 11.03. | Boehringer Ingelheim Places €25M Bet on Sosei's Novel Approach to Schizophrenia | 10 | MedCity News | ||
| 11.03. | Boehringer, Sosei Heptares Partner on Schizophrenia Precision Treatment | 3 | Contract Pharma | ||
| 11.03. | Boehringer boosts schizophrenia strategy with €25M upfront for option on Sosei's GPR52 agonists | 3 | FierceBiotech | ||
| 11.03. | Boehringer licenses Sosei schizophrenia drugs in €755m deal | 2 | pharmaphorum | ||
| 11.03. | Boehringer and Sosei Heptares partner on schizophrenia treatment | 2 | Pharmaceutical Technology | ||
| 11.03. | Sosei Group Corporation: Boehringer Ingelheim and Sosei Heptares join forces to develop first-in-class treatments targeting all symptoms of schizophrenia | 164 | GlobeNewswire (Europe) | Single-target agreement focused on development of novel, small molecule agonists of GPR52 discovered by Sosei Heptares with the potential to simultaneously address positive, negative and cognitive... ► Artikel lesen | |
| 06.03. | Sosei Heptares Earns $2.5M Formosa Milestone | 1 | Contract Pharma |
Seite:
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 23,875 | -0,19 % | Labcorp Receives FDA Approval for First Companion Diagnostic for Use with Pfizer's Newly Approved Gene Therapy to Treat Patients with Hemophilia B | Assay expands company's leadership in precision medicine and cell and gene therapy
BURLINGTON, N.C., April 29, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive... ► Artikel lesen | |
| NOVARTIS | 91,01 | -0,05 % | Novartis Pharma AG: Novartis erzielt im ersten Quartal ein zweistelliges Umsatzwachstum und steigert die Kerngewinnmarge; Prognose für das Geschäftsjahr 2024 erhöht | Ad-hoc-Mitteilung gemäss Art. 53 KR
Der Nettoumsatz wuchs im ersten Quartal um +11% (kWk1, +10% USD), das operative Kernergebnis verbesserte sich um +22% (kWk, +16% USD)
Die wichtigsten Wachstumstreiber... ► Artikel lesen | |
| GILEAD SCIENCES | 61,38 | -0,29 % | Gilead Sciences Aktie: Umsatzeinbußen vorhergesagt | Gilead Sciences, ein führendes Biotechnologieunternehmen, steht vor der Bekanntgabe seiner Ergebnisse für das erste Quartal 2024 am 25. April nach Börsenschluss. Die Umsatzprognosen deuten auf leichte... ► Artikel lesen | |
| SANOFI | 91,76 | +0,34 % | BERNSTEIN RESEARCH stuft SANOFI auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat das Kursziel für Sanofi von 108 auf 114 Euro angehoben und die Einstufung auf "Outperform" belassen. Der Pharmakonzern habe im... ► Artikel lesen | |
| ABBVIE | 150,80 | +0,12 % | Earnings: AbbVie: Gewinn pro Aktie steigt um 492,3 Prozent - Prognose angehoben! | © Foto: Sipa USA | SOPA Images - picture allianceAbbVie hat heute seine Finanzergebnisse für das erste Quartal 2024 vorgelegt, die ein deutliches Wachstum zeigen.AbbVie meldete einen verwässerten Gewinn... ► Artikel lesen | |
| ROCHE | 226,80 | -0,04 % | F. Hoffmann-La Roche Ltd: [Ad hoc-Mitteilung gemäss Art. 53 KR] Verkäufe der Roche-Gruppe steigen im ersten Quartal um 2% (CER); beide Divisionen Pharma und Diagnostics wachsen im hohen einstelligen Bereich ohne COVID-19-Produkte | Konzernverkäufe stiegen um 2%1 zu konstanten Wechselkursen (CER; -6% in CHF) dank starkem Wachstum der jüngeren Medikamente und Diagnostika; ohne COVID-19-Produkte nahmen die Konzernverkäufe um 7% zu... ► Artikel lesen | |
| ABBOTT LABORATORIES | 99,52 | -0,56 % | Abbott's Dissolving Stent For People With Chronic Limb-Threatening Ischemia Gets FDA Nod | NORTH CHICAGO (dpa-AFX) - Abbott Laboratories (ABT) Monday announced that the U.S. Food and Drug Administration has approved the Esprit BTK Everolimus Eluting Resorbable Scaffold System for... ► Artikel lesen | |
| HAEMATO | 17,000 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM XETRA - 17.04.2024 | The following instruments on XETRA do have their last trading day on 17.04.2024Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 17.04.2024ISIN NameDE000LB32W75 LBBW FZA 22/24DE000DW6C4A6... ► Artikel lesen | |
| INCYTE | 49,050 | -0,02 % | Verhaltene Kauflaune bei Incyte-Aktie (48,5695 €) | CODE Das Papier notiert gegenwärtig bei 51,98 US-Dollar. Der Kurs der Aktie von Incyte zeigt sich derzeit kaum verändert im Vergleich zu der letzten Notierung des vorigen Handelstages. Zur Stunde steht... ► Artikel lesen | |
| EDWARDS LIFESCIENCES | 79,74 | -0,55 % | Edwards Lifesciences Corp. Q1 Profit Increases, beats estimates | WASHINGTON (dpa-AFX) - Edwards Lifesciences Corp. (EW) revealed a profit for its first quarter that increased from last year and beat the Street estimates.The company's earnings totaled $351.9... ► Artikel lesen | |
| WPD PHARMACEUTICALS | 0,027 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 23.04.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 23.04.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 23.04.2024ISIN NameAU000000AC89 AUSCANN... ► Artikel lesen | |
| HALEON | 3,919 | -0,41 % | Haleon CFO Tobias Hestler Resigns; Names Replacement | LONDON (dpa-AFX) - U.K.-headquartered consumer healthcare business Haleon plc (HLN) on Wednesday said its Chief Financial Officer Tobias Hestler decided to resign on health grounds, with effect... ► Artikel lesen | |
| BIONANO GENOMICS | 0,865 | +10,04 % | Bionano Genomics: Bionano Announces Publication Showing that OGM Detects Over 1250 Structural Variants, including 56 Gene Fusions, in Pediatric Leukemia that were Missed by Whole Genome Sequencing | SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study from Penn State College of Medicine that used optical genome mapping... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 0,180 | 0,00 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces Presentation at Planet MicroCap Showcase | ||
| GRIFOLS | 8,600 | -0,02 % | GRIFOLS, S.A.: The Company reports the signing subject to customary closing conditions of the private offering of EUR 1 billion of senior secured notes. |
NXERA PHARMA CO LTD gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 8,500 Euro und damit -0,58 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
